Billiontoone Closes $125M Series C Funding With Premier Global Investors

Mar 30, 2022•over 3 years ago

Amount Raised

$125 Million

Round Type

series c

Menlo Park

Description

BillionToOne, Inc., a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announces the closure of an oversubscribed Series C funding round of $125 million with premier global investors. This round was co-led by incoming investor Adams Street Partners and existing investor Hummingbird Ventures with significant participation from Baillie Gifford, Neotribe Ventures, Norwest Venture Partners, Civilization Ventures, Fifty Years VC, Pacific 8 Ventures, Time BioVentures, and Libertus Capital, among others.

Company Information

Company

Billion To One

Location

Menlo Park, California, United States

About

BillionToOne, headquartered in Menlo Park, California, is a precision diagnostics company with a mission to make molecular diagnostics more accurate, efficient, and accessible for all. The company's patent-pending QCT molecular counter platform is the only technology platform that can accurately count DNA molecules at the single-count level. BillionToOne's flagship product, UNITY, is the first and only noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis (CF), spinal muscular atrophy (SMA), and hemoglobinopathies through maternal blood. BillionToOne was co-founded by Oguzhan Atay, Ph.D. and David Tsao, Ph.D. For more information, visit www.billiontoone.com.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech